<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348163</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0480</org_study_id>
    <nct_id>NCT03348163</nct_id>
  </id_info>
  <brief_title>(mo)BETTA Trial in Transwomen for Optimization of ART</brief_title>
  <acronym>(mo)BETTA</acronym>
  <official_title>Bictegravir, Emtricitabine and Tenofovir Alafenamide in Transwomen for Optimization of ART: The (mo)BETTA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of a new HIV&#xD;
      medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV&#xD;
      medications combined into one pill) in HIV-infected transgender women (TW).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Maintaining Undetectable HIV-1 RNA</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of participants who maintain &lt;50 copies/mL HIV-1 RNA for 48 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of participants who discontinue study drug due to study-drug related adverse events (AEs, includes &gt;/= Grade 3 lab or clinical events)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lean mass</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in lean mass (total, limb) as measured by Dual-energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Mass</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in fat mass (total, trunk, limb) as measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in BMD as measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Fat Content</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change hepatic fat content as measured by FibroScan controlled attenuation parameter (CAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in total cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in HDL cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in Triglyceride level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin level</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in Insulin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose level</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in Glucose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in Number of participants with insulin resistance as measured by the homeostatic assessment model of insulin resistance (HOMA-IR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Switch ART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch from current antiretroviral therapy (ART) to B/FTC/TAF bfor 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continue Current ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continue current (ART) therapy (emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent) for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/FTC/TAF</intervention_name>
    <description>B/FTC/TAF in one pill (single tablet regimen) for administration to participants in Arm A.</description>
    <arm_group_label>Switch ART</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Current ART</intervention_name>
    <description>Comparator arm. Participant continues open label entry ART.</description>
    <arm_group_label>Continue Current ART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-identified transgender woman (TW)&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Undetectable HIV viral load (HIV-1 RNA &lt;50 copies/mL) at screening and for &gt;/=24 weeks&#xD;
             prior to entry.&#xD;
&#xD;
          -  Current HIV treatment with FTC plus TDF or TAF and a 3rd agent.&#xD;
&#xD;
          -  No changes in ART in the 12 weeks prior to screening.&#xD;
&#xD;
          -  Current female hormone therapy use.&#xD;
&#xD;
          -  Ability and willingness of subject to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or planned use of prohibited medications (Phenobarbital, Phenytoin,&#xD;
             Carbamazepine, Oxcarbazepine, Rifampin, Rifapentine, St. John's Wort, Echinacea,&#xD;
             Dofetilide, Cisapride, Atazanavir)&#xD;
&#xD;
          -  Change or initiation of lipid- and/or glucose-lowering therapy in the 12 weeks prior&#xD;
             to entry, or planned need for such therapy during the study period.&#xD;
&#xD;
          -  Current use of androgen therapy.&#xD;
&#xD;
          -  Intent to significantly modify diet or exercise habits, or to enroll in a weight loss&#xD;
             intervention during the study period.&#xD;
&#xD;
          -  Anticipated need to initiate or change doses of medications with anti-inflammatory&#xD;
             properties within the study period.&#xD;
&#xD;
          -  Screening laboratory values as follows: (ANC &lt;500 cells/mm^3; Hemoglobin &lt;10 gm/dL; Cr&#xD;
             Cl &lt;30 mL/min (estimated by CKD-Epi equation); AST or ALT &gt;3x ULN)&#xD;
&#xD;
          -  Evidence of resistance to any component of the current ART regimen (genotypic or&#xD;
             phenotypic)&#xD;
&#xD;
          -  Current use of bictegravir in another investigational setting&#xD;
&#xD;
          -  Current use of other investigational agents that the participant could not receive&#xD;
             unchanged, if needed, throughout the study period (unless approved by the study team)&#xD;
&#xD;
          -  Any condition that the study investigator believes would make the candidate unsuitable&#xD;
             for participation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-identified transgender women (TW)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan E Lake, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordan E Lake, MD</last_name>
    <phone>(713) 500-6759</phone>
    <email>Jordan.E.Lake@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kayla Bishop</last_name>
    <phone>(713) 500-6797</phone>
    <email>ms.HARTresearchstudyinfo@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thomas Street Health Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Bishop</last_name>
      <phone>713-500-6797</phone>
      <email>ms.HARTresearchstudyinfo@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Jordan Elizabeth Lake</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Transgender women</keyword>
  <keyword>Bictegravir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

